INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4901, 27162, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4902, 27163, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4903, 27171, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4904, 27172, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4905, 27173, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4906, 27174, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4907, 27175, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4908, 27176, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4909, 27177, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4910, 27178, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4911, 27179, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4912, 27180, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4913, 27182, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4914, 27183, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4915, 27188, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4916, 27189, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4917, 27191, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4918, 27192, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4919, 27196, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4920, 27197, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4921, 27198, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4922, 27199, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4923, 27200, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4924, 27201, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4925, 27202, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4926, 27204, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4927, 27205, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4928, 27206, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4929, 27207, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4930, 32245, 'Magnesium chloride', 'Cholestasis', 'The trace elements, copper and manganese, are excreted in the bile.  Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4931, 2503, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4932, 5458, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4933, 7636, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4934, 8792, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4935, 9463, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4936, 10172, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4937, 10173, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4938, 10174, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4939, 10620, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4940, 10622, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4941, 10624, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4942, 10628, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4943, 10630, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4944, 10631, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4945, 15669, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4946, 23719, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4947, 24160, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4948, 24161, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4949, 24748, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4950, 25089, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4951, 25090, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4952, 25091, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4953, 25092, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4954, 25093, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4955, 26479, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4956, 27093, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4957, 27152, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4958, 27155, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4959, 27156, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4960, 27157, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4961, 27158, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4962, 27161, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4963, 27162, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4964, 27163, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4965, 27171, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4966, 27172, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4967, 27173, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4968, 27174, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4969, 27175, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4970, 27176, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4971, 27177, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4972, 27178, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4973, 27179, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4974, 27180, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4975, 27182, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4976, 27183, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4977, 27188, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4978, 27189, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4979, 27191, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4980, 27192, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4981, 27196, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4982, 27197, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4983, 27198, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4984, 27199, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4985, 27200, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4986, 27201, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4987, 27202, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4988, 27204, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4989, 27205, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4990, 27206, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4991, 27207, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4992, 32245, 'Magnesium chloride', 'Malabsorption Syndromes', 'The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements.  GI absorption may be decreased in patients with malabsorption syndromes.  Therefore, larger dosages may be required when these supplements are given orally.  Parenteral administration may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4993, 0, 'Maraviroc', 'Liver Failure', 'Hepatotoxicity has been reported with the use of maraviroc.  Severe rash or evidence of systemic allergic reaction (e.g., fever, eosinophilia, elevated immunoglobulin E [IgE]) prior to the development of hepatotoxicity may occur.  Patients with signs/symptoms of hepatitis or allergic reaction after use of maraviroc should be evaluated immediately.  Appropriate laboratory testing (including ALT, AST, and bilirubin) should be conducted before starting maraviroc and periodically during therapy as clinically indicated.  Additional monitoring may be necessary when administering maraviroc to patients with preexisting liver dysfunction or who are coinfected with hepatitis B and/or C virus.  The safety and efficacy of maraviroc has not been studied in patients with significant underlying liver disorders; caution is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4994, 0, 'Maraviroc', 'Kidney Diseases', 'An increased risk of postural hypotension may occur in patients with severe renal dysfunction or in those with ESRD due to increased exposure to maraviroc in some patients.  This drug should be used with caution in these patients only if they are not receiving a concomitant potent CYP450 3A inhibitor or inducer, but maraviroc should only be considered for patients with severe renal dysfunction or ESRD when no alternative treatment options are available.  The dose should be reduced if any symptoms of postural hypotension occur.  No studies have been performed in patients with severe renal dysfunction (CrCl less than 30 mL/min) or ESRD who are concomitantly taking potent CYP450 3A inhibitors or inducers, and maraviroc is contraindicated in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4995, 0, 'Maraviroc', 'Cardiovascular Diseases', 'Cardiovascular events (including myocardial ischemia and/or infarction) were reported in 11 therapy-experienced patients (1.3%) receiving maraviroc during phase 3 trials; these patients generally had cardiac disease or cardiac risk factors before using maraviroc.  Patients with cardiovascular comorbidities, history of/risk factors for postural hypotension, or receiving concurrent medication known to lower blood pressure, could be at increased risk of cardiovascular adverse events triggered by postural hypotension; additional monitoring may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4996, 0, 'Lutetium Lu 177 dotatate', 'Liver Diseases', 'Lutetium Lu 177 dotatate does not undergo hepatic metabolism.  No dose adjustment is recommended for patients with mild or moderate hepatic impairment.  Care is recommended when using lutetium Lu 177 dotatate in patients with severe hepatic impairment (total bilirubin > 3 times upper limit of normal and any AST) as its safety has not been studied in these patients.  Monitor transaminases, bilirubin and serum albumin during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4997, 0, 'Lutetium Lu 177 dotatate', 'Bone Marrow Failure Disorders', 'The use of lutetium Lu 177 dotatate may increase the risk of developing myelosuppression.  Care should be exercised when using this agent in immunocompromised patients.  It is recommended to monitor blood cell counts.  Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4998, 0, 'Lutetium Lu 177 dotatate', 'Kidney Diseases', 'Lutetium Lu 177 dotatate predominantly undergoes renal excretion.  No dose adjustment is recommended for patients with mild to moderate renal impairment.  It is recommended to assess renal function frequently in patients with mild to moderate impairment during therapy with this agent.  .  Monitor serum creatinine and calculated creatinine clearance.  The safety of lutetium Lu 177 dotatate in patients with severe renal impairment or end-stage renal disease has not been studied', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (4999, 3797, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5000, 3935, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
